Oncolytics Biotech Inc T.ONC

Roche to name a new CEO by March 2023

[Noteable]

The Roche CEO successor will be a company veteran.

https://www.bloomberg.com/news/articles/2023-01-11/roche-is-looking-inward-for-new-pharma-chief-as-pressure-grows?leadSource=uverify%20wall

https://www.fiercepharma.com/pharma/another-leadership-change-roche-anderson-departs-pharma-sector-ceo

[Noteable]

The apparent choice for the pharma chief’s job would be Alexander Hardy, who succeeded former Roche CEO Bill Anderson as Genentech CEO in 2019.

[Noteable]

Given the recent develoments in Roche's preclinical/clinical R&D set backs with anti-TIGIT and CD47 targets - Roche's yet-to-be-announced CEO will have some quick decisions and already fermenting M&A announcements to make when he takes office sometimes before March. 

[westcoast1000]

I guess we have to wait for the new CEO, and related new team members, to come on board before they pay serious attention to ONCY. Too bad. Note they will want some quick wins, and we may offer that with the panc results and synergy with Tecentriq.

[Noteable]

There is no expected changes in management or team members other than the already announced change in CEO. And decisions on acquisition targets have been made. The only thing will be for the new CEO to review and rubber-stamp what has most likely has been decided on, except for the acquisition value - which will likely signficant higher now for ONCY, for example, given the demise of Roche's

[Noteable]

A quick win for Big Pharma is ONCY's "Phase 3 ready" / potential accelerated approval candidate pelareorep in pancreatic and breast cancer.

[Noteable]

February 02, 2023 -  "Roche's head of global product strategy, Teresa Graham, will take over as CEO of Roche Pharmaceuticals in March while the company’s corporate executive committee will make a spot for Levi Garraway, CMO and executive VP of global product development. Thomas Schinecker will take over the top spot as Roche group CEO in March, leaving his spot as head of

[Noteable]

February 08, 2023 - Former Roche Pharmaceuticals CEO  Bill Anderson, will become Bayer’s new group CEO starting in April. On February 2nd Roche named Teresa Graham as CEO of Roche Pharmaceuticals. https://www.fiercepharma.com/pharma/bayer-taps-roche-vet-anderson-its-next-ceo-pushing-out-baumann

[Angler101]

Noteable, to reiterate on azzack’s question, do you think Oncy’s association with Chinese co. Adlai Nortye could be detrimental to a buyout by not only Pfizer, but by any big pharma?

[Angler101]

Personally,  although I’m far from any kind of authority on multi-billion dollar buyouts, I can’t see it being a deal-breaker. When billions are involved, one would think that a minor inconvenience like this would have a way of disappearing easily enough.

[Noteable]

Not a deal-breaker what-so-ever. In fact the AN "surrender' of the AN/ONCY licensing agreement clears the way for a smooth take-over of ONCY.

[Noteable]

Just remember that pelareorep will be used in combination with a Big Pharma's PD-(L)1 inhibitor and we don't yet know which one that will be. Neither does AN. So rather than complicate potential ONCY's acquisition by a Big Pharma partner with an obscure "licensing agreement" that does not have an identified immune checkpoint inhibitor, AN prudently cleared the way for the

[Noteable]

Should read ... " So rather than complicate ONCY's potential acquisition by big Pharma ..... AN prudently cleared the way for the Big Pharma to move on ONCY " .... without any incumberances for Big Pharma to ultimately have to deal with.

[itntdf]

again, how did AN "clear the way"? ANY approved use of pela with any other "agent" in AN's territory benefits AN with a double digit royalty going to oncy or its successor.  any big pharma that wants to obtain approval for ANYTHING using pela in AN's territory is limited by the AN agreement and would be settling for a double digit royalty.

[itntdf]

again, where are you seeing that AN surrendered anything?

[Angler101]

Itntdf.....maybe you did not, but I took it he was continuing on his I would think narrative....it does seem plausible.....I mean it’s all only about money and how much

[itntdf]

exactly how does it seem plausible that AN would walk away from any use of pela when it purchased those rights for $80k, milestone payments, and the payment of double digit royalties for a population making up nearly 20% of the world's total? oh yeah, right.  they'll just give up potentiall billions of dollars in sales to make things easier for big pharma to take out oncy and then

[Angler101]

I would say it would be highly plausible in several ways such as if big pharma threw them a big pile of cash, or if they decided on a partnership with each other, for starters.....

[itntdf]

those answers are plausible but they were not part of the explanation about which i took issue. whomever were to take out oncy would already have some type of agreement with AN, whether or not it would make sense to reduce it to a formal partnership would be up to the buyer. how much $ is "retaking" 20% of the world's population re: the use of pela for any and all approved

[Angler101]

Itntdf.....with all due respect, I don’t think anyone, including notable was suggesting AN was going to walk away for a pittance..... but although AN’s position does look admittedly rose, remember their deal with Oncy included royalty payments, when, instead of doing any deal, they could have just placed a few spies into Oncy’s ranks(they’re probably there already) and simply have stolen the IP